Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 12/20 | 1.00 |
| ▸ | F10 | P00742 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29456385 | 1.00 | F2 (1.00) | F2F10POLB | |
| SCHEMBL8028409 | 1.00 | F2 (1.00) | F2F10POLB | |
| Hydrochloric Acid SCHEMBL6544370 | 1.00 | F2 (1.00) | F2F10POLB | |
| Hydrochloric Acid SCHEMBL6543183 | 0.96 | F2 (0.92) | F2F10POLB | |
| SCHEMBL6607979 | 0.96 | F2 (0.92) | F2F10POLB | |
| SCHEMBL6607983 | 0.96 | F2 (0.92) | F2F10POLB | |
| Hydrochloric Acid SCHEMBL6543190 | 0.96 | F2 (0.92) | F2F10POLB | |
| SCHEMBL6543512 | 0.93 | F2 (0.87) | F2F10POLB | |
| SCHEMBL6543495 | 0.93 | F2 (0.87) | F2F10POLB | |
| SCHEMBL6543472 | 0.89 | F2 (0.80) | F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268469-B1 | N-(HETEROCYCLYL)BENZENE OR PYRIDINE SULPHONAMIDES AS ANTITHROMBOTIC AGENTS AND ANTICOAGULANTS | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | claimed |
| US-6680329-B2 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | SANOFI-SYNTHELABO (FR) | 2004-01-20 | — | — | US | claimed |
| US-20030207920-A1 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | SANOFI-AVENTIS (FR) | 2003-11-06 | — | — | US | claimed |
| US-6680329-B2 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | SANOFI-SYNTHELABO (FR) | 2004-01-20 | — | — | US | disclosed |
| US-20030207920-A1 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | SANOFI-AVENTIS (FR) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207920-A1 | N-(heterocyclyl)benzene or pyridinesulphonamides as antithrombotic agents and anticoagulants | PROC, VKORC1, SERPINC1 | F2 7/4885F10 99/4885POLB 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.